Sanofi (SAN.PA, SNY) Wins EU Approval for Cenrifki, First Non-Relapsing SPMS Therapy

Sanofi (SAN.PA, SNY) announced on June 23, 2026, that the European Commission has granted marketing authorization for Cenrifki (osocimab). This approval positions Cenrifki as the first disability-targeting therapy for non-relapsing secondary progressive multiple sclerosis (SPMS), addressing a critical unmet medical need for patients without relapses. Cenrifki, an investigational CXCR4 antagonist, aims to mitigate brain atrophy and slow disability progression. The company anticipates launching the drug in Germany during the third quarter of 2026, with other EU countries to follow. The approval is supported by data from the Phase 2b OSCAR study, which demonstrated Cenrifki's ability to significantly reduce brain volume loss and delay disability progression in the specified SPMS patient population.